Cerebrospinal fluid biomarkers in Parkinson disease

Nature Reviews Neurology

Volumn 9, Issue 3, 2013, Pages 131-140

  Parnetti, Lucilla ^a   Castrioto, Anna ^a   Chiasserini, Davide ^b   Persichetti, Emanuele ^a   Tambasco, Nicola ^a   El Agnaf, Omar ^c   Calabresi, Paolo ^d  

^a UNIVERSITY OF PERUGIA   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; LYSOSOME ENZYME; TAU PROTEIN;

AUTOPHAGOSOME; CEREBROSPINAL FLUID; CONTROLLED STUDY; DIAGNOSTIC ERROR; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; EARLY DIAGNOSIS; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PARKINSON DISEASE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW;

AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; INTERMEDIATE FILAMENT PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ONCOGENE PROTEINS; PARKINSON DISEASE;

EID: 84874948898     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.10     Document Type: Review

References (129)

1. Lees, A. J., Hardy, J. & Revesz, T. Parkinson's disease. Lancet 373, 2055-2066 (2009).
2. Wu, Y., Le, W. & Jankovic, J. Preclinical biomarkers of Parkinson disease. Arch. Neurol. 68, 22-30 (2011).
3. Marras, C. & Lang, A. Parkinson's disease subtypes: lost in translation? J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp- 2012-303455.
4. van Dijk, K. D. et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol. Dis. 39, 229-241 (2010).
5. Dubois, B. et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 1118-1127 (2010).
6. McKhann, G. M. Changing concepts of Alzheimer disease. JAMA 305, 2458-2459 (2011).
7. Nyhlen, J., Constantinescu, R. & Zetterberg, H. Problems associated with fluid biomarkers for Parkinson's disease. Biomark. Med. 4, 671-681 (2010).
8. Parnetti, L. et al. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26, 1428-1435 (2011).
9. Giasson, B. I., Lee, V. M. & Trojanowski, J. Q. Interactions of amyloidogenic proteins. Neuromolecular Med. 4, 49-58 (2003).
10. Giasson, B. I. et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636-640 (2003).
11. Waxman, E. A. & Giasson, B. I. Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J. Neurosci. 31, 7604-7618 (2011).
12. Lee, V. M., Giasson, B. I. & Trojanowski, J. Q. More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases. Trends Neurosci. 27, 129-134 (2004).
13. Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J. & Stefanis, L. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 10, 1015-1025 (2011).
14. Westbroek, W., Gustafson, A. M. & Sidransky, E. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol. Med. 17, 485-493 (2011).
15. Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651-1661 (2009).
16. Velayati, A., Yu, W. H. & Sidransky, E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr. Neurol. Neurosci. Rep. 10, 190-198 (2010).
17. Dehay, B. et al. Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30, 12535-12544 (2010).
18. Gegg, M. E. et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol. 72, 455-463 (2012).
19. Shachar, T. et al. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov. Disord. 26, 1593-1604 (2011).
20. Hong, Z. et al. DJ 1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726 (2010).
21. Jakes, R., Spillantini, M. G. & Goedert, M. Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32 (1994).
22. George, J. M. The synucleins. Genome Biol. 3, reviews3002.1-reviews3002.6 (2002).
23. Tozzi, A. et al. Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice. Neurobiol. Aging 33, 1792-1799 (2012).
24. Irvine, G. B., El Agnaf, O. M., Shankar, G. M. & Walsh, D. M. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol. Med. 14, 451-464 (2008).
25. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473 (1998).
26. Spillantini, M. G. et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208 (1998).
27. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
28. Kruger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108 (1998).
29. Zarranz, J. J. et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173 (2004).
30. Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841-841 (2003).
31. Chartier Harlin, M. C. et al. α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169 (2004).
32. Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307 (2009).
33. Simon-Sanchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312 (2009).
34. El-Agnaf, O. M., Jakes, R., Curran, M. D. & Wallace, A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440, 67-70 (1998).
35. Hashimoto, M. et al. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 799, 301-306 (1998).
36. Conway, K. A., Harper, J. D. & Lansbury, P. T. Jr. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563 (2000).
37. El-Agnaf, O. M. et al. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid like filaments. FEBS Lett. 440, 71-75 (1998).
38. Borghi, R. et al. Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287, 65-67 (2000).
39. Mollenhauer, B. et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213, 315-325 (2008).
40. Mollenhauer, B. et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-240 (2011).
41. Tokuda, T. et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166 (2006).
42. Tateno, F., Sakakibara, R., Kawai, T., Kishi, M. & Murano, T. α-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 26, 213-216 (2012).
43. Noguchi-Shinohara, M. et al. CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 1251, 1-6 (2009).
44. Ohrfelt, A. et al. Cerebrospinal fluid α-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett. 450, 332-335 (2009).
45. Spies, P. E., Melis, R. J., Sjögren, M. J., Rikkert, M. G. & Verbeek, M. M. Cerebrospinal fluid α-synuclein does not discriminate between dementia disorders. J. Alzheimers Dis. 16, 363-369 (2009).
46. Aerts, M. B., Esselink, R. A., Abdo, W. F., Bloem, B. R. & Verbeek, M. M. CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 33, 430.e1-430.e3 (2012).
47. Tokuda, T. et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166 (2006).
48. Winner, B. et al. In vivo demonstration that α-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194-4199 (2011).
49. Xu, J. et al. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600-606 (2002).
50. Paleologou, K. E. et al. Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132, 1093-1101 (2009).
51. Sharon, R. et al. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595 (2003).
52. El-Agnaf, O. M., Walsh, D. M. & Allsop, D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol. 2, 461-462 (2003).
53. Tokuda, T. et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766-1772 (2010).
54. Park, M. J., Cheon, S. M., Bae, H. R., Kim, S. H. & Kim, J. W. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J. Clin. Neurol. 7, 215-222 (2011).
55. Sierks, M. R. et al. CSF levels of oligomeric alpha synuclein and beta amyloid as biomarkers for neurodegenerative disease. Integr. Biol. (Camb.) 3, 1188-1196 (2011).
56. Foulds, P. G. et al. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol. Dis. 45, 188-195 (2011).
57. Wang, Y. et al. Phosphorylated α-synuclein in Parkinson's disease. Sci. Transl. Med. 4, 121ra20 (2012).
58. Bartels, T., Choi, J. G. & Selkoe, D. J. α-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110 (2011).
59. Wang, W. et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc. Natl Acad. Sci. USA 108, 17797-17802 (2011).
60. Fauvet, B. et al. α-synuclein in the central nervous system and from erythrocytes, mammalian cells and Escherichia coli exists predominantly as a disordered monomer. J. Biol. Chem. 287, 15345-15364 (2012).
61. Bonifati, V. et al. Mutations in the DJ 1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2003).
62. Waragai, M. et al. Increased level of DJ 1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345, 967-972 (2006).
63. Shi, M. et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69, 570-580 (2011).
64. Shi, M. et al. DJ 1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol. Aging 33, 836.e5-836.e7 (2011).
65. Aarsland, D., Bronnick, K., Larsen, J. P., Tysnes, O. B. & Alves, G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian Park West study. Neurology 72, 1121-1126 (2009).
66. Aarsland, D. & Kurz, M. W. The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci. 289, 18-22 (2010).
67. Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837-844 (2008).
68. Ballard, C. et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67, 1931-1934 (2006).
69. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
70. Jellinger, K. A. & Attems, J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 115, 427-436 (2008).
71. Hansen, L. et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 40, 1-8 (1990).
72. Clinton, L. K., Blurton Jones, M., Myczek, K., Trojanowski, J. Q. & LaFerla, F. M. Synergistic interactions between Aβ, tau, and α-synuclein: acceleration of neuropathology and cognitive decline. J. Neurosci. 30, 7281-7289 (2010).
73. Masliah, E. Recent advances in the understanding of the role of synaptic proteins in Alzheimer's Disease and other neurodegenerative disorders. J. Alzheimers Dis. 3, 121-129 (2001).
74. Calabresi, P., Picconi, B., Parnetti, L. & Di Filippo, M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol. 5, 974-983 (2006).
75. Jellinger, K. A. Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener. Dis. 5, 118-121 (2008).
76. Blennow, K. & Hampel, H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2, 605-613 (2003).
77. Bateman, R. J. et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1 (2012).
78. Mollenhauer, B. et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 22, 200-208 (2006).
79. 42 and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25, 2682-2685 (2010).
80. Parnetti, L. et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol. Psychiatry 64, 850-855 (2008).
81. Sjögren, M. et al. Decreased CSF-β-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord. 13, 112-118 (2002).
82. Alves, G. et al. CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian Park West study. J. Neurol. Neurosurg. Psychiatry 81, 1080-1086 (2010).
83. 1-42 CSF levels in different phenotypes of Parkinson's disease. J. Neural Transm. 119, 353-362 (2011).
84. Siderowf, A. et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology 75, 1055-1061 (2010).
85. Blennow, K. et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26, 231-245 (1995).
86. Mollenhauer, B. et al. Tauopathies and synucleinopathies: do cerebrospinal fluid β-amyloid peptides reflect disease-specific pathogenesis? J. Neural Transm. 114, 919-927 (2007).
87. Zhang, J. et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129, 526-529 (2008).
88. Přikrylová Vranová, H. et al. CSF markers of neurodegeneration in Parkinson's disease. J. Neural Transm. 117, 1177-1181 (2010).
89. Andersson, M., Zetterberg, H., Minthon, L., Blennow, K. & Londos, E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. Int. J. Geriatr. Psychiatry 26, 100-105 (2011).
90. Bech, S. et al. Amyloid related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat. Disord. 18, 69-72 (2012).
91. Buongiorno, M., Compta, Y. & Marti, M. J. Amyloid-β and τ biomarkers in Parkinson's disease-dementia. J. Neurol. Sci. 310, 25-30 (2011).
92. Bibl, M. et al. CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 1177-1187 (2006).
93. Compta, Y. et al. Cerebrospinal tau, phospho-tau, and beta amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. 24, 2203-2210 (2009).
94. Leverenz, J. B. et al. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 17, 61-64 (2011).
95. Burack, M. A. et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74, 77-84 (2010).
96. 11C]PIB binding in Parkinson's disease dementia. Neuroimage 39, 1027-1033 (2008).
97. Alves, G. et al. Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp-2012-303808.
98. Jellinger, K. A. CSF biomarkers in different phenotypes of Parkinson disease. J. Neural Transm. 119, 455-456 (2012).
99. 42 levels in Lewy body disease. J. Alzheimers Dis. 22, 933-938 (2010).
100. Wang, Y. et al. Complement 3 and factor H in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am. J. Pathol. 178, 1509-1516 (2011).
101. Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. Cell 132, 27-42 (2008).
102. Mizushima, N. Autophagy: process and function. Genes Dev. 21, 2861-2873 (2007).
103. Vogiatzi, T., Xilouri, M., Vekrellis, K. & Stefanis, L. Wild type α-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283, 23542-23556 (2008).
104. Anglade, P. et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12, 25-31 (1997).
105. Chen, Y., McMillan Ward, E., Kong, J., Israels, S. J. & Gibson, S. B. Mitochondrial electron transport chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. J. Cell Sci. 120, 4155-4166 (2007).
106. Dagda, R. K., Zhu, J., Kulich, S. M. & Chu, C. T. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy 4, 770-782 (2008).
107. Zhu, J. H. et al. Regulation of autophagy by extracellular signal regulated protein kinases during 1 methyl 4 phenylpyridinium induced cell death. Am. J. Pathol. 170, 75-86 (2007).
108. Cataldo, A. M., Barnett, J. L., Pieroni, C. & Nixon, R. A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J. Neurosci. 17, 6142-6151 (1997).
109. Barrachina, M., Maes, T., Buesa, C. & Ferrer, I. Lysosome associated membrane protein 1 (LAMP 1) in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 32, 505-516 (2006).
110. Neudorfer, O. et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89, 691-694 (1996).
111. Bultron, G. et al. The risk of Parkinson's disease in type 1 Gaucher disease. J. Inherit. Metab. Dis. 33, 167-173 (2010).
112. Cherin, P. et al. The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). J. Inherit. Metab. Dis. 33, 331-338 (2010).
113. Grabowski, G. A. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372, 1263-1271 (2008).
114. Aharon-Peretz, J., Badarny, S., Rosenbaum, H. & Gershoni Baruch, R. Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype genotype correlation. Neurology 65, 1460-1461 (2005).
115. De Marco, E. V. et al. Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov. Disord. 23, 460-463 (2008).
116. Spitz, M., Rozenberg, R., Pereira Lda, V. & Reis Barbosa, E. Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat. Disord. 14, 58-62 (2008).
117. Sun, Q. Y. et al. Glucocerebrosidase gene L444P mutation is a risk factor for Parkinson's disease in Chinese population. Mov. Disord. 25, 1005-11 (2010).
118. Clark, L. N. et al. Pilot association study of the β- glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov. Disord. 20, 100-103 (2005).
119. Roze, E., Navarro, S., Cornu, P., Welter, M. L. & Vidailhet, M. Deep brain stimulation of the globus pallidus for generalized dystonia in GM1 Type 3 gangliosidosis: technical case report. Neurosurgery 59, E1340 (2006).
120. Wu, G. et al. Decreased activities of lysosomal acid alpha D galactosidase A in the leukocytes of sporadic Parkinson's disease. J. Neurol. Sci. 271, 168-173 (2008).
121. Wu, G. et al. Decreased expression of lysosomal alpha-galactosidase A gene in sporadic Parkinson's disease. Neurochem. Res. 36, 1939-1944 (2011).
122. Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 (2011).
123. Balducci, C. et al. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov. Disord. 22, 1481-1484 (2007).
124. Parnetti, L. et al. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in dementia with Lewy Bodies. Neurobiol. Dis. 34, 484-486 (2009).
125. Mollenhauer, B. & Zhang, J. Biochemical premotor biomarkers for Parkinson's disease. Mov. Disord. 27, 644-650 (2012).
126. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629-635 (2011).
127. Lehnert, S. et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp. Neurol. 234, 499-505 (2012).
128. Picotti, P. & Aebersold, R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods 9, 555-566 (2012).
129. Lee, H. J., Khoshaghideh, F., Patel, S. & Lee, S. J. Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 24, 1888-1896 (2004).